| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/01/2023 | 417.24% | Benchmark | → $9 | Reiterates | Buy → Buy |
| 08/14/2023 | 187.36% | Stifel | $9 → $5 | Maintains | Buy |
| 07/21/2023 | 244.83% | Stephens & Co. | → $6 | Reiterates | Overweight → Overweight |
| 05/09/2023 | 417.24% | Benchmark | $15 → $9 | Maintains | Buy |
| 05/09/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/17/2023 | 704.6% | Piper Sandler | $21 → $14 | Maintains | Overweight |
| 02/27/2023 | 417.24% | HC Wainwright & Co. | $15 → $9 | Maintains | Buy |
| 01/19/2023 | 1221.84% | Piper Sandler | $22 → $23 | Maintains | Overweight |
| 11/07/2022 | 762.07% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 08/08/2022 | 1336.78% | HC Wainwright & Co. | $27 → $25 | Maintains | Buy |
| 07/18/2022 | 1451.72% | HC Wainwright & Co. | $38 → $27 | Maintains | Buy |
| 07/15/2022 | 1106.9% | Cowen & Co. | $39 → $21 | Maintains | Outperform |
| 07/15/2022 | 1164.37% | Piper Sandler | $35 → $22 | Maintains | Overweight |
| 05/11/2022 | 1164.37% | Stephens & Co. | $26 → $22 | Maintains | Overweight |
| 11/05/2021 | 2083.91% | HC Wainwright & Co. | $33 → $38 | Maintains | Buy |
| 10/15/2021 | 1796.55% | HC Wainwright & Co. | $28 → $33 | Maintains | Buy |
| 08/06/2021 | 1509.2% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 06/18/2021 | 1451.72% | HC Wainwright & Co. | $26 → $27 | Maintains | Buy |
| 04/12/2021 | 1739.08% | Piper Sandler | → $32 | Initiates Coverage On | → Overweight |
| 03/01/2021 | 1624.14% | Stifel | → $30 | Initiates Coverage On | → Buy |
| 02/26/2021 | 1394.25% | HC Wainwright & Co. | $21 → $26 | Maintains | Buy |
| 05/11/2020 | 1106.9% | HC Wainwright & Co. | $22.5 → $21 | Reiterates | → Buy |
| 01/17/2019 | — | First Analysis | Upgrades | Neutral → Outperform |
What is the target price for Codexis (CDXS)?
The latest price target for Codexis (NASDAQ: CDXS) was reported by Benchmark on September 1, 2023. The analyst firm set a price target for $9.00 expecting CDXS to rise to within 12 months (a possible 417.24% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Codexis (CDXS)?
The latest analyst rating for Codexis (NASDAQ: CDXS) was provided by Benchmark, and Codexis reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Codexis (CDXS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Codexis, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Codexis was filed on September 1, 2023 so you should expect the next rating to be made available sometime around September 1, 2024.
Is the Analyst Rating Codexis (CDXS) correct?
While ratings are subjective and will change, the latest Codexis (CDXS) rating was a reiterated with a price target of $0.00 to $9.00. The current price Codexis (CDXS) is trading at is $1.74, which is within the analyst's predicted range.